alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EXHIBIT 31  SECTION 302 CERTIFICATIONS

I, Theodore L. Arena, and I, Thomas J. Mulroney, each separately certify that:

1. I have reviewed this quarterly report on Form 10-Q of Provena Foods Inc. (the Company);

2. Based on my knowledge, this report does
not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by
this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;

4. The
Companys other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and l5d-15(e)) for the Company and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure
that material information relating to the Company, including any subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Evaluated the effectiveness of the Companys disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

c) Disclosed in this report any change in the Companys internal control over financial reporting that occurred during the Companys most recent fiscal quarter that has materially affected, or is reasonably likely to materially
affect, the Companys internal control over financial reporting; and

5. The Companys other certifying officer and I have disclosed, based on
our most recent evaluation of internal control over financial reporting, to the Companys auditors and the audit committee of the Companys board of directors:

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Companys ability to record,
process, summarize and report financial information; and

b) Any fraud. whether or not material, that involves management or other
employees who have a significant role in the Companys internal control over financial reporting.

Date: November 2, 2006



|                                           
|-------------------------------------------
|/s/ Theodore L. Arena                      
|Theodore L. Arena, Chief Executive Officer 
|                                           
|/s/ Thomas J. Mulroney                     
|Thomas J. Mulroney, Chief Financial Officer
#### § 710.5 Amendments to registration.

Within 30 days after a change in any of the information contained on a submitted Form FD-2511, a new Form FD-2511 should be submitted to amend the registration. This amendment is also necessary when a registration is to be canceled because an establishment has changed its name and no longer conducts business under the original name.
#### Victor Manufacturing and Gasket Co., a Corporation, Plaintiff-Appellee, v. City of Chicago, a Municipal Corporation, Defendant-Appellant.

Gen. No. 53,144. (Abstract of Decision.)

First District, Second Division.

May 20, 1969.

Raymond P. Simon, Corporation Counsel of the City *343of Chicago (Marvin E. Aspen and RocLyne E. LaPorte, Assistant Corporation Counsels, of counsel), for appellant;

no brief filed for appellee.

Opinion by

MR. PRESIDING JUSTICE LYONS.

Not to be published in full.
<PAGE>   1

                                                                    EXHIBIT 24.2


                                POWER OF ATTORNEY


         Know by all these presents, that the undersigned hereby constitutes and
appoints Gordon A. Gardiner and Larry W. Martin, or either of them, the
undersigned's true and lawful attorney-in-fact to:

         (1)      execute for and on behalf of the undersigned, in the
                  undersigned's capacity as a director of Data Dimensions, Inc.
                  (the "Company"), a registration statement on Form S-8,
                  registering 157,625 shares of the Company's Common Stock
                  issuable upon exercise of options granted pursuant to the ST
                  Labs 1995 and 1997 Stock Option Plans.

         (2)      do and perform any and all acts or and on behalf of the
                  undersigned which may be necessary or desirable to complete
                  and execute any such registration statement on Form S-8 and
                  timely file such registration statement with the United States
                  Securities and Exchange Commission and any stock exchange or
                  similar authority; and

         (3)      take any other action of any type whatsoever in connection
                  with the foregoing which, in the opinion of such
                  attorney-in-fact, may be of benefit to, in the best interest
                  of, or legally required by, the undersigned, it being
                  understood that the documents executed by such
                  attorney-in-fact on behalf of the undersigned pursuant to this
                  Power of Attorney shall be in such form and shall contain such
                  terms and conditions as such attorney-in-fact may approve in
                  such attorney-in-fact's discretion.

         The undersigned hereby grants to such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this Power of Attorney and the rights and powers herein
granted.

         This Power of Attorney shall remain in full force and effect until
revoked by the undersigned in a signed writing delivered to the foregoing
attorney-in-fact.

         IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney
to be executed as of this _____ day of ___________________, 1998.

                                             /s/ LUCIE J. FJELDSTAD
                                             -----------------------------------
                                             Lucie J. Fjeldstad
**Exhibit 32.2**

 

**FIRST MARINER BANCORPCERTIFICATION PURSUANT TO18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

 

Pursuantto, and for purposes only of, 18 U.S.C. § 1350, I, Mark A. Keidel, ChiefFinancial Officer of First Mariner Bancorp (the “Company”) hereby certify that(i) the Annual Report of the Company on Form 10-K for the year endedDecember 31, 2005 filed with the Securities and Exchange Commission (the “Report”)fully complies with the requirements of Section 13(a) or 15(d) of theSecurities Exchange Act of 1934, and (ii) information contained in the Reportfairly presents, in all material respects, the financial condition and resultsof operations of the Company.

 
| Dated:  March 16, 2006 | /s/ Mark A.  Keidel      |   |
|-----------------------------|--------------------------|--------|
|                        | Mark A. Keidel           |
|                        | Chief Financial  Officer |

 

----
Order entered November 29, 2016

In The

Court of Appeals 

Fifth District of Texas at Dallas 

No. 05-15-01144-CR

ERNEST EDWARD GAINES, Appellant

V.

THE STATE OF TEXAS, Appellee

On Appeal from the 282nd Judicial District Court

Dallas County, Texas

Trial Court Cause No. F05-56570-S

ORDER

Before the Court is Ernest Gaines’s November 21, 2016 Motion for Extension of Time to 

File Appellant’s Brief. Gaines tendered his appellate brief contemporaneously with the motion. 

On November 17, 2016, on our own motion, we ordered Gaines, through counsel, to file his brief 

by November 28, 2016. Accordingly, we DENY Gaines’s November 21, 2016 motion as moot. 

We DIRECT the Clerk to file the brief tendered by Gaines on November 21, 2016.

/s/ ROBERT M. FILLMORE 

JUSTICE
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1420 Isocitric dehydrogenase test system. ( a ) *Identification.* An isocitric dehydrogenase test system is a device intended to measure the activity of the enzyme isocitric dehydrogenase in serum and plasma. Isocitric dehydrogenase measurements are used in the diagnosis and treatment of liver disease such as viral hepatitis, cirrhosis, or acute inflammation of the biliary tract; pulmonary disease such as pulmonary infarction (local arrest or sudden insufficiency of the blood supply to the lungs), and diseases associated with pregnancy.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
[52 FR 16122, May 1, 1987, as amended at 53 FR 21449, June 8, 1988; 66 FR 38788, July 25, 2001]
# C_2014315EN.01006301.xml

| 15.9.2014 | EN | Official Journal of the European Union | C 315/63 |
| --- | --- | --- | --- |

15.9.2014

EN

Official Journal of the European Union

C 315/63

---

Order of the General Court of 27 June 2014 — Mogyi v OHIM

(Case T-8/14) (1)

1

((Community trade mark - Revocation of the decision of the Board of Appeal - No need to adjudicate))

2014/C 315/105

Language of the case: Hungarian

Parties

Parties

Applicant: Mogyi Kft (Csávoly, Hungary) (represented by: Zs.J. Klauber, lawyer)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (represented by: P. Sipos and A. Folliard-Monguiral, acting as Agents)

Defendant:

Re:

Re:

Action brought against the decision of the First Board of Appeal of OHIM of 19 September 2013 (Case R 1921/2012-1) concerning an application for registration of the word sign Just crunch it... as a Community trade mark.

Operative part of the order

Operative part of the order

| 1. | It is no longer necessary to adjudicate on the action. |
| --- | --- |

1.

It is no longer necessary to adjudicate on the action.

| 2. | The defendant shall bear its own costs and pay those incurred by the applicant. |
| --- | --- |

2.

The defendant shall bear its own costs and pay those incurred by the applicant.

---

(1)  OJ C 71, 8.3.2014.

1

---
5000

5800

5400

5800

7200

5000

5000

5200

5200

5400

6200

7200

6400

6400

5200

5000

4400

5400

4800

4600

4800

6000

6200

4400

7400

4400

5200

5400

7000

4800

4400

5200

5600

6800

6000

4800

5200

81

81

81

C O U N T Y R D -C 011

C O U N T Y R D -C 011

C O U N T Y R D -C 010 C O U N T Y R D -C 01 3

C O U N T Y R D -C 011

C O U N T Y R D -C 011

C O U N T Y R D -C 011

81

81

81

C O U N T Y R D -C 011

C O U N T Y R D -C 011

C O U N T Y R D -C 010 C O U N T Y R D -C 01 3

C O U N T Y R D -C 011

C O U N T Y R D -C 011

C O U N T Y R D -C 011

Big

Tank

Playa

s

Valley

Thompson Canyon

Big

Hatchet

Mountains

U

B

ar Rid

g

e

Humble

Number 1

Humble

Number 1

Proverbial

Gypsum

Keiths

Ranch

Robertsons

Ranch

Mosse

Ranch

Horse

Mountain

Sentinel

Butte

U Bar

Ridge

Big

Hatchet

Peak

Walnut

Wells NE

Pierce

Peak

Hilo

Peak

Hatchet

Ranch

Sheridan

Canyon

34

000m

YV

108°

00

27' 25'

30"

108°

E

34

97

7

27'

44

94

93

7

32'

98

30"

96

000

7 2

95

35

34

2

30"

35'

108°

90

34

108°

30'

550

7 7

7 31° 7

30'

89

30"

7

30"

7 46

42

34

7

96

7

YA

38

88

YA

30" 7

22'

47

34

45

35

43

95

000m

01

38

FEET

7

N

00

43

35

220

34

31°

000m

7

34

FEET

32'

22'

34

35

34

7

34

91

01

35'

44 49 31°

37'

40

N

47

40

190

7

34

30"

89

30"

34

000m

34

41 46 30'

92

3499

34

520

39 42

000

34

000 FEET 7 7 48 E

99

7

98

34

37'

93

34

000 FEET

34

34

31° 30'

94

92

25'

YV

91

U.S. DEPARTMENT OF THE INTERIOR

U. S. GEOLOGICAL SURVEY

NEW MEXICO

ADJOINING 7.5' QUADRANGLES

QUADRANGLE LOCATION

U BAR RIDGE, NM

2010

Interstate Route State Route

ROAD CLASSIFICATION

Interstate Route US Route State Route

Ramp 4WD

US Route Local Road

U BAR RIDGE QUADRANGLE

NEW MEXICO

7.5-MINUTE SERIES

Zone 12R

North American Datum of 1983 (NAD83)

World Geodetic System of 1984 (WGS84). Projection and

1 000-meter grid: Universal Transverse Mercator,

Produced by the United States Geological Survey

10 000-foot ticks: New Mexico Coordinate System of 1983

(west zone)

Imagery...............................NAIP, January 2005 - May 2009

Roads..............................................©2006-2010 Tele Atlas

Names...............................................................GNIS, 2008

Hydrography.................National Hydrography Dataset, 2005

Contours............................National Elevation Dataset, 2001

1000 500 0 METERS 1000 2000

1000 0 1000 2000 3000 4000 5000 6000 7000 8000 9000 10000

FEET

This map was produced to conform with version 0.5.10 of the

draft USGS Standards for 7.5-Minute Quadrangle Maps.

A metadata file associated with this product is draft version 0.5.11

SCALE 1:24 000

1 0.5 0 1

MILES

MN

1 0.5 0 KILOMETERS 1 2

GN

UTM GRID AND 2010 MAGNETIC NORTH DECLINATION AT CENTER OF SHEET

1° 20 ́

24 MILS

9° 39 ́

172 MILS

U.S. National Grid

100,000-m Square ID

Grid Zone Designation

12R

YV

YA 35 00

CONTOUR INTERVAL 40 FEET

NORTH AMERICAN VERTICAL DATUM OF 1988
# C_2018005EN.01004201.xml

| 8.1.2018 | EN | Official Journal of the European Union | C 5/42 |
| --- | --- | --- | --- |

8.1.2018

EN

Official Journal of the European Union

C 5/42

---

Order of the General Court of 25 October 2017 — Novartis Europharm v Commission

(Case T-511/14) (1)

1

((Medicinal products for human use - Marketing authorisation for the medicinal product Zoledronic acid Teva Generics - Zoledronic acid - Period of protection of the medicinal product Aclasta containing the active substance zoledronic acid - Withdrawal of the contested measure - No need to adjudicate))

(2018/C 005/56)

Language of the case: English

Parties

Parties

Applicant: Novartis Europharm Ltd (Camberley, United Kingdom) (represented by: C. Schoonderbeek, lawyer)

Applicant:

Defendant: European Commission (represented by: A. Sipos and M. Wilderspin, Agents)

Defendant:

Re:

Re:

Action brought under Article 263 TFEU seeking annulment of Commission Implementing Decision C(2014) 2155 final of 27 March 2014 granting a marketing authorisation to Teva Generics BV for the medicinal product for human use Zoledronic acid Teva Generics — Zoledronic Acid under Article 3 of Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (OJ 2004 L 136, p. 1).

Operative part of the order

Operative part of the order

| 1. | There is no longer any need to adjudicate on the action. |
| --- | --- |

1.

There is no longer any need to adjudicate on the action.

| 2. | There is no longer any need to adjudicate on Teva BV’s application for leave to intervene. |
| --- | --- |

2.

There is no longer any need to adjudicate on Teva BV’s application for leave to intervene.

| 3. | Each party shall bear its own costs. |
| --- | --- |

3.

Each party shall bear its own costs.

---

(1)  OJ C 388, 3.11.2014.

1

---
39073.

#### RICE *et al.*v. MATTHEWS, Administratrix.

Decided October 6, 1961.

*594
      *Powell, Goldstein, Frazer & Murphy, 'Edward E. Dorsey, C. B. Rogers,*for plaintiffs in error.

*Augustine Sams, Emory Kinard,*contra.

Ebbrhardt; Judge.

Since the new trial here was granted on special grounds of the amended motion, and not on discretionary grounds, it does not fall within the rule that the first grant of a new trial shall not be disturbed. *Code*§ 6-1608, as amended by the act of 1959 (Ga. L. 1959, pp. 353, 354).

There must be no expression of opinion on the facts by the court in its charge to the jury, and if such there be, a new trial must be granted. *Code*§ 81-1104.

We are persuaded that the trial judge felt that there was some expression of opinion by him, in view of the conflict in the testimony, that Matthews did test a peril that he had observed. If the jury believed that Matthews was walking along the street near to and parallel with the curb, then this portion of the charge would have no application; it would come into play only if they should conclude that he was walking across the street and that he, after observing Mrs. Rice coming only a few feet away, determined that he would get across in front of her. This was not explained to the jury, and we are constrained to agree that they may have concluded that the judge was expressing an opinion *595that it was this situation, rather than that contended by plaintiff, with which Matthews was faced and with which he dealt. The trial judge; having delivered the charge, and having come to the conclusion that he committed error in the expression of an opinion, his grant of a new trial ought to be affirmed unless the record clearly, unmistakably and unequivocally demonstrates that no opinion was expressed.

*Judgment affirmed.*

*Carlisle, P. J., and*Nichols, *J., concur.*
§ 333.210 Antifungal active ingredients. The active ingredient of the product consists of any one of the following within the specified concentration established for each ingredient: ( a ) Clioquinol 3 percent.
( b ) Haloprogin 1 percent.
( c ) Miconazole nitrate 2 percent.
( d ) Povidone-iodine 10 percent.
( e ) Tolnaftate 1 percent.
( f ) Undecylenic acid, calcium undecylenate, copper undecylenate, and zinc undecylenate may be used individually or in any ratio that provides a total undecylenate concentration of 10 to 25 percent.
( g ) Clotrimazole 1 percent.
[58 FR 49898, Sept. 23, 1993, as amended at 67 FR 5943, Feb. 8, 2002]
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1680 Testosterone test system. ( a ) *Identification.* A testosterone test system is a device intended to measure testosterone (a male sex hormone) in serum, plasma, and urine. Measurement of testosterone are used in the diagnosis and treatment of disorders involving the male sex hormones (androgens), including primary and secondary hypogonadism, delayed or precocious puberty, impotence in males and, in females hirsutism (excessive hair) and virilization (masculinization) due to tumors, polycystic ovaries, and adrenogenital syndromes.
( b ) *Classification.* Class I.
[52 FR 16122, May 1, 1987; 53 FR 11645, Apr. 8, 1988]
#### § 822.35 Can you inspect my manufacturing site or other sites involved in my postmarket surveillance plan?

We can review your postmarket surveillance programs during regularly scheduled inspections, inspections initiated to investigate recalls or other similar actions, and inspections initiated specifically to review your postmarket surveillance plan. We may also inspect any other person or site involved in your postmarket surveillance, such as investigators or contractors. Any person authorized to grant access to a facility must permit authorized FDA employees to enter and inspect any facility where the device is held or where records regarding postmarket surveillance are held.
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute of Child Health and Human Development Special Emphasis Panel, Mechanisms of Acclimatization (Perinatology).                    

*Date:*                         April 1, 2010.                    

*Time:*                         1 p.m. to 3:30 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         National Institutes of Health, 6100 Executive Boulevard, Room 5B01, Bethesda, MD 20892. (Telephone Conference Call)                    

*Contact Person:*                         Rita Anand, PhD, Scientific Review Officer, Division of Scientific Review, Eunice Kennedy Shriver National Institute, of Child Health and Human Development, NIH, 6100 Executive Blvd. Room 5B01, Bethesda, MD 20892, (301) 496-1487,                         *anandr@mail.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS)

Dated: February 25, 2010.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2010-4480 Filed 3-3-10; 8:45 am]

BILLING CODE 4140-01-P